Core Binding Factor Acute Myeloid Leukemia
generalAcute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.
60
Centers
15
Active Trials
$13.3B
Cancer Funding
Specific Cancer Types(1)
Top Centers for Core Binding Factor Acute Myeloid Leukemia(60)
Ranked by research excellence score (trials · grants · publications). Methodology →
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →